Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dalton Medicinal Chemistry Partners, the medicinal chemistry arm of Dalton Pharma Services, has achieved a targeted milestone in its medicinal chemistry agreement with Boehringer Ingelheim Canada. The achievement of the milestone has led to payment of an undisclosed amount.
Subscribe to our email newsletter
Dalton Medicinal Chemistry Partners is utilizing its medicinal chemistry expertise to design and synthesize novel compounds against an antiviral target selected by Boehringer Ingelheim (Canada).
Peter Pekos, president of Dalton Pharma Services, said: “We are pleased to achieve this milestone in our exciting partnership with Boehringer Ingelheim (Canada) Ltd. It is a pleasure working with the talented team at Boehringer Ingelheim.”